Tumor lysis syndrome
- G1Laboratory tumor lysis syndrome (LTLS) AND creatinine >ULN - 1.5 × ULN
- G2LTLS AND creatinine >1.5 – 3.0 × ULN; cardiac arrhythmia managed medically; one brief generalized seizure; seizure(s) well controlled by anticonvulsants; infrequent focal motor seizures not limiting age-appropriate instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)
- G3LTLS AND creatinine >3.0 – 6.0 × ULN; cardiac arrhythmia controlled with device (e.g. defibrillator); seizure in which consciousness is altered; poorly controlled seizure disorder; breakthrough generalized seizures despite medical intervention
- G4LTLS AND creatinine >6.0 x ULN; life-threatening cardiac arrhythmia or seizure
- G5Death
Definition and note
DefinitionA disorder characterized by metabolic abnormalities that result from a spontaneous or therapy-related cytolysis of tumor cells. Clinical tumor lysis syndrome (CTLS) requires one or more clinical manifestations along with criteria for laboratory tumor lysis syndrome (LTLS). LTLS is defined by two or more of the following laboratory abnormalities within 3 days before or 7 days after the initiation of chemotherapy: Uric acid ≥ 476 mcmol/L or 25% increase from baseline, Potassium ≥ 6.0 mmol/L or 25% increase from baseline, Phosphorous ≥ 2.1 mmol/L (children), ≥1.45 mmol/L (adults) or 25% increase from baseline, Calcium ≤ 1.75 mmol/L or 25% decrease from baseline.
MedDRA code (LLT): 10045152 · CTCAE v6.0 (NCI), original English text.